These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20854203)

  • 1. HIV-1 diversity after a class switch failure.
    Kolber MA; Buendia P; Degruttola V; Moore RD
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1175-80. PubMed ID: 20854203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
    Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
    Manfredi R; Calza L; Chiodo F
    J Antimicrob Chemother; 2002 May; 49(5):723-9. PubMed ID: 12003964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
    Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
    Seu L; Mulenga LB; Siwingwa M; Sikazwe I; Lambwe N; Guffey MB; Chi BH
    J Med Virol; 2015 Jul; 87(7):1149-57. PubMed ID: 25754408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.
    Lorenzen T; Walther I; Stoehr A; Salzberger B; Plettenberg A;
    Infection; 2009 Dec; 37(6):528-33. PubMed ID: 19826762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chantratita W
    Curr HIV Res; 2008 Sep; 6(5):474-6. PubMed ID: 18855659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
    Chaplin B; Eisen G; Idoko J; Onwujekwe D; Idigbe E; Adewole I; Gashau W; Meloni S; Sarr AD; Sankalé JL; Ekong E; Murphy RL; Kanki P
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):71-80. PubMed ID: 20964479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
    Marconi VC; Sunpath H; Lu Z; Gordon M; Koranteng-Apeagyei K; Hampton J; Carpenter S; Giddy J; Ross D; Holst H; Losina E; Walker BD; Kuritzkes DR;
    Clin Infect Dis; 2008 May; 46(10):1589-97. PubMed ID: 18419495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
    Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
    Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.
    Masquelier B; Neau D; Chêne G; Larbère J; Birac V; Ragnaud JM; Fleury HJ
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):309-12. PubMed ID: 11707665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.